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The ongoing reluctance to proclaim 
two breast cancer drugs proven to slow 
early disease progression and save lives 
for specific indications has frustrated 
State medical oncologists anxious to 
thrash out a speedy solution, especially 
in the Western Cape.
They are in urgent talks with 
resource-constrained Western Cape 
and national pharmaceutical coding 
committees, whom they say have 
quibbled for years, citing drug cost 
inequities, cost inefficiencies and data 
paucity on ‘life years’. Widely known 
as the most prevalent cancer in women 
nationally, the only available caseload 
data (National Cancer Registry, 1999) 
put annual breast cancer diagnoses in 
South Africa at 6 000, with the lifetime 
risk for women at 1 in 27.
Texanes, a class of drugs which show 
overall survival benefits of about 5% 
and proven non-recurrence benefits in 
early-stage diagnosis, would cost the 
country about R120 million annually 
(based on an estimate of 2 000 early-
stage public sector patients). 
Trastuzumab (Herceptin) on the other 
hand, boasts a 50% decrease in relapse 
and a one-third improvement in 
survival in a potentially curable setting, 
making it a highly attractive clinical 
option. Used together, they can be 
highly effective.
However there is one snag: 
trastuzumab would cost about R200 
million per annum to theoretically cure 
just 30 women (based on 600 eligible 
public sector patients), raising the cost 
bar to what coding committee members 
regard as impossible heights.
Professor Paul Ruff, head of 
medical oncology at Wits University/ 
Johannesburg General Hospital, who 
made these calculations ‘for illustrative 
purposes only’ told Izindaba that it 
‘basically comes down to a money 
issue’. He said taxanes were available 
on public sector hospital codes in 
Gauteng and KwaZulu-Natal but in 
very few, if any, other provinces. He 
confirmed that there was no uniform 
national drug committee proclamation 
on either drug.
Western Cape oncologists are now 
engaging more fully with their own 
committee, which has displayed what 
some of them earlier regarded as a fatal 
lack of urgency.
Professor Justus Apffelstaedt, head 
of the multidisciplinary breast clinic at 
Tygerberg Hospital, estimates, based on 
First-World data, that the lack of wider 
availability of texanes alone costs ‘too 
many’ lives annually in his province.
Apffelstaedt, whose Tygerberg clinic 
treats about 350 new cases of breast 
cancer a year, said texanes  increased 
absolute survival rates in the USA by 
2 - 4% (in populations that generally 
reported far earlier for treatment than 
was usual in South Africa).
SA breast cancer treatment 
‘suboptimal’
He claimed texanes would push up 
the survival rate in the Western Cape 
by ‘at least double these percentages’, 
translating to a ‘significant number’ of 
lives a year (based on 1 000 new breast 
cancer cases per year). ‘With texanes, 
breast cancer patients will recover more 
often and earlier,’ he asserted, adding 
that its non-availability was particularly 
frustrating when it was being used 
in equivalent public sector facilities 
elsewhere.
‘What’s excruciating is that the 
pharmaceutical coding committee has 
had motivations from us four times in 
as many years and turned them down 
on ludicrous grounds. We can see they 
don’t have a clue about oncology and 
what’s needed’. Apffelstaedt said that 
for the typical public sector patient 
presenting with low-key pre-metastatic 
breast cancer, texanes presented a 14.7% 
better chance of them being alive in 
10 years’ time than with the currently 
available CMF-like chemotherapy.
Texanes and trastuzumab are on 
the WHO guidelines for breast cancer 
treatment and are internationally 
considered highly appropriate clinical 
therapies.
A senior specialist in clinical and 
radiation oncology, who did not wish to 
be named for fear of damaging the ‘very 
constructive relationship’ with the drug 
committees, said there were ‘massive’ 
studies in texanes and trastuzumab for 
curative therapy.
‘Sure, I don’t jump up and down 
about the texanes metanalysis where the 
overall post-metastatic survival benefit 
is about 5%, but trastuzumab with its 
50% decrease in relapse and so far  a 
one-third improvement in survival in 
a potentially curable setting, is worth 
going for!’
‘The drug committee keeps asking 
us for qualies (quality-of-life year 
measurements). I’ve had several 
individual (pre-metastatic) applications 
turned down in the last year.’
Many medical oncologists want to 
use trastuzumab with texanes in a 
curative setting, especially where other 
chemotherapy is contraindicated. One 
charged: ‘We have almost no lines of 
treatment here for breast cancer. In the 
private sector you give one and then 
another, or a ‘top dressing’. Their team 
had ‘bust a gut’ to obtain approval for 
the drugs, to no avail.
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Drug manufacturer Roche had 
promised the local public sector 
oncologists a ‘special price’ from 
overseas several years ago, but this 
never materialised.
Drug committee member replies 
A senior member of their province’s 
pharmaceutical coding committee and 
member of the national tertiary and 
quaternary Essential Drugs List (EDL) 
committee, who also asked not to be 
named for fear of ‘creating an unhelpful 
climate’, said the issue was ‘complex’.
Reporting the issue in ‘an emotive 
way’ belied the complex health 
economics, ‘unconvincing’ quality-of-life 
data and the ethical considerations of 
formulating a consistent and equitable 
drug policy in a resource-poor setting. 
He did add, however, ‘they’ve been 
slow to ask and we’ve been slow to 
respond’, admitting that the provincial 
committee had been ‘somewhat 
obstructive because we’re trying to 
develop a (uniform) national policy on 
how we look at oncology’.
From a brutal cost point of view, 
the dilemma for funding breast cancer 
drugs centres on relative and absolute 
risk; in other words, does one proclaim 
drug therapies for saving and/or 
prolonging lives and, if so, what is the 
quality of the lives so prolonged?
The committee member said he hoped 
this would be rectified nationally for 
texanes before the year’s end, but ruled 
out trastuzumab as ‘just too expensive’.
‘I think that in the next 3 - 4 months 
(from August), we’ll have data on 
texanes for every condition, so it can be 
a definite yes or no,’ he said. He claimed 
the texanes data were inconclusive, 
mainly because most studies were in 
populations with advanced metastatic 
disease.
Professor Bettina Taylor, Head of 
Health Policy at Medscheme Health 
Risk Solutions and a member of 
UCT’s Research Ethics Committee, 
said confrontation between clinical 
policy makers and treating doctors was 
‘not unexpected, given the different 
perspectives’. The policy makers often 
cited the huge price tags for drugs as 
unjustified by the extra months of life 
they might offer and, perhaps more 
importantly, other lives lost as a result 
of limitations of the health care system. 
The ‘lost opportunity’ costs of allocating 
additional funds to expensive new 
drugs had to be considered, she said, 
citing a potentially ‘more effective’ 
reduction of breast cancer deaths by 
channelling the same funds towards 
improving surgery waiting lists.
Listing chemotherapeutic agents 
on provincial and national drug 
lists provided them with Prescribed 
Minimum Benefit (PMB) status – a 
vital factor in the ongoing debate. Such 
listing would impact negatively on the 
affordability of such options and further 
deepen the inequity of the existing PMB 
package.
She added that, given the link 
between public and private sector drug 
policy, it was ‘somewhat unfortunate’ 
that the representatives of the private 
funding industry had to date, to the best 
of her knowledge, not been consulted in 
the collation of the EDL.
Private medical schemes currently 
paid for taxanes and trastuzumab, but 
access within lower contribution options 
tended to be limited to keep the scheme 
affordable.
Oncologists ‘suddenly got 
louder’
The Izindaba drug committee source 
said medical oncology had ‘generally 
been very quiet’, but in the last year 
became very vocal, ‘motivating us 
more, probably because of international 
clinician peer pressure’.
Because of the overlap between the 
national and local coding processes, 
‘we thought it useful to let the national 
process run its course. There’s so much 
emotionality it’s worthwhile having a 
team effect, even if it is slower.’
He explained his ‘lack of data’ 
rationale thus: ‘We’re caught up in an 
ethical dilemma because the clinical trial 
scenario is moving but there’s been no 
declaration on the cost-effectiveness of 
the backbone therapy’.
The majority of biological plausibility 
studies of new agents were conducted 
in metastatic disease before being tested 
in a primary setting. ‘With breast cancer 
if you catch it early and give chemo 
you can aim for cure, that’s the gold 
standard. Then if patients present late 
and there’s a metastatic disorder and 
you’re not curing, they’re going to die, 
but it will take a long time,’ he said.
He said the mantra of oncologists was 
that ‘some therapy must be offered’. 
‘However we have to ask, how much 
longer do they live?’
While texanes had shown biological 
plausibility in many cancers, the only 
data his committee had on texanes were 
for metastatic ovarian carcinoma. ‘We 
ask for quality-of-life data that make 
for cost efficiency, but we’re caught 
up in this scenario that the drugs are 
internationally recognisable and our 
guys (clinicians) are embarrassed’.
Now that the matter had ‘come to 
a head, we’re going to sit down and 
try and find a mechanism for moving 
forward’. It would be ‘inequitable to 
put carcinoma on a pedestal’, when 
other diseases deserved to be judged on 
the same criteria. ‘Nor can we accept 
slightly immature data on breast cancer,’ 
he added.
In the UK the National Institute 
of Clinical Excellence paid out the 
‘I think that in the next 3 - 4 
months (from August), we’ll 
have data on texanes for 
every condition, so it can be 
a definite yes or no,’ he said.
Confrontation between 
clinical policy makers 
and treating doctors was 
‘not unexpected, given the 
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November 2008, Vol. 98, No. 11  SAMJ
Izindaba November.indd   834 10/16/08   4:02:28 PM
IZINDABA
836
equivalent of between R435 000 and 
R580 000 for one quality-adjusted life-
year. ‘In resource-poor settings we just 
don’t have the same value. It sounds 
terrible, but what is the value of a life? 
We’re the ones who have to divvy out 
the money!’
Ruff said about 40% of breast cancers 
occurred in Gauteng, 25% in the 
Western Cape, with KwaZulu-Natal and 
the Free State together totalling about 
30%. The remaining 5% occurred in 
provinces with little or no appropriate 
health care infrastructure.
‘We don’t really know what we’re 
doing because the cancer data are so 
bad in this country,’ he cautioned.
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